Durairaj, A., & Ramamurthi, R. (2019). Prevalence, pattern and predictors of premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) among college girls. New Indian J OBGYN, 5(2), 93-98.
Hofmeister, S., & Bodden, S. (2016). Premenstrual Syndrome and Premenstrual Dysphoric Disorder. Am Fam Physician, 94(3), 236-240.
Kim, N., Yoo, H.-N., Hyun, H. S., Lee, D.-Y., Yoon, B.-K., & Choi, D.-S. (2015). Efficacy and safety of a 24-day regimen of drospirenone-containing combined oral contraceptive in Korean women. Obstetrics & gynecology science, 58(5), 397-400.
Lopez, L. M., Kaptein, A. A., & Helmerhorst, F. M. (2012). Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane database of systematic reviews(2).
Marr, J., Heinemann, K., Kunz, M., & Rapkin, A. (2011). Ethinyl estradiol 20 μg/drospirenone 3 mg 24/4 oral contraceptive for the treatment of functional impairment in women with premenstrual dysphoric disorder. International Journal of Gynecology & Obstetrics, 113(2), 103-107.
Reid, R. L. (2017). Premenstrual dysphoric disorder (formerly premenstrual syndrome). Endotext [Internet].
Ryu, A., & Kim, T. H. (2015). Premenstrual syndrome: A mini review. Maturitas, 82(4), 436-440. https://doi.org/10.1016/j.maturitas.2015.08.010